Jubilant Pharmova Ltd

Jubilant Pharmova has appointed Daniel J. O'Connor as CEO of Jubilant Therapeutics Inc. step down subsidiary of the company. Powered by Capital Market - Live

The board of Jubilant Pharmova at its meeting held on 31 October 2025 has approved the Grant of 1,506 Stock Options/ Restricted Stock Units (RSUs) to the eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018.Powered by Capital Market - Live

Net profit of Jubilant Pharmova rose 17.02% to Rs 120.30 crore in the quarter ended September 2025 as against Rs 102.80 crore during the previous quarter ended September 2024. Sales rose 12.38% to Rs 1957.80 crore in the quarter ended September 2025 as against Rs 1742.20 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1957.801742.20 12 OPM %17.4316.61 - PBDT300.90250.00 20 PBT196.10158.60 24 NP120.30102.80 17 Powered by Capital Market - Live

Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 31 October 2025.Powered by Capital Market - Live

Jubilant Pharmova announced today that Jubilant HollisterStier LLC (JHS)'a wholly owned subsidiary and a leading North American pharmaceutical contract manufacturer, specialising in sterile injectables and serving top global innovator pharma companies'successfully launched its New Sterile Fill & Finish line, third at its Spokane Manufacturing Facility in Washington, US. The launch was marked by the successful production of the inaugural batch, initiating revenue generation from the new Line. This milestone denotes a significant advancement in Jubilant HollisterStier's multi-phase expansion strategy and brings an additional 50% capacity at its Spokane manufacturing facility. The New Line features advanced isolator technology designed to deliver enhanced sterility assurance, throughput and operational precision. Built to meet the highest global regulatory standards, the New Line significantly enhances the Company's ability to support complex injectable programs across a broad range of therapeutic areas. The US$ 132 million investment towards this New Third Line, reflects the Company's long-term commitment to innovation, quality and supply chain resilience. Together with the commissioning of its upcoming Fourth Line, JHS is on track to double its total sterile injectable manufacturing capacity at its Spokane facility in the US. This strategic investment further reinforces JHS' leadership in domestic US pharmaceutical manufacturing. By expanding its infrastructure and increasing onshore capacity, the Company is contributing to US national health security and helping to reduce reliance on offshore supply chains' delivering a more resilient and agile pharmaceutical manufacturing ecosystem. Powered by Capital Market - Live

'The appointment is made for an interim period to ensure a smooth transition to the new CFO, for which the identification and appointment process is in progress,' the company stated in regulatory filing. Arun Kumar Sharma is a strategic and result-driven financial leader with over three decades of progressive experience across corporate finance, global treasury, investor relations, risk management, financial restructuring, insurance, capex control, and business transformation. He has held various positions in Jubilant Bhartia Group including CFO role in Jubilant Pharma Holdings Inc. USA for approximately 4 years, Jubilant Lifesciences (Chemical Business) for approximately 3 years and Jubilant Pharmova for around 2 years (April' 2021-May'2023). Jubilant Pharmova is a globally present company engaged in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, contract research, development and manufacturing (CRDMO), generics, and proprietary novel drugs businesses. The company's consolidated net profit declined 78.66% to Rs 102.90 crore despite a 9.21% rise in revenue to Rs 1,878.90 crore in Q1 FY26 over Q1 FY25. The counter was down 0.65% to currently trade at Rs 1084.95 on the BSE.Powered by Capital Market - Live

Jubilant Cadista is a subsidiary of Jubilant Pharma, which is the wholly owned subsidiary Jubilant Pharmova. The said inspection was completed on 19 September 2025. The inspection closed with no observations. 'The above inspection concluded with zero observations, reaffirming Jubilant commitment to maintaining the highest standards of quality, safety, and compliance,' the company said in a statement. Jubilant Pharmova is a globally present company engaged in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, contract research, development and manufacturing (CRDMO), generics, and proprietary novel drugs businesses. The company's consolidated net profit declined 78.66% to Rs 102.90 crore despite a 9.21% rise in revenue to Rs 1,878.90 crore in Q1 FY26 over Q1 FY25. The scrip was up 0.41% to currently trade at Rs 1107.95 on the BSE. Powered by Capital Market - Live

Jubilant Pharmova announced that the Annual General Meeting(AGM) of the company will be held on 29 August 2025.Powered by Capital Market - Live

Jubilant Pharmova announced that the United States Food and Drug Administration (USFDA) has concluded pre-approval inspection (PAI) of the solid dosage formulations facility on August 01, 2025 at Roorkee site, India of Jubilant Generics ('Company'), a subsidiary of its wholly owned subsidiary Jubilant Pharma. The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations. The site's revenue from the US market in the trailing twelve month period (July'24 to June'25) is less than one percent of Jubilant Pharmova revenues in the same period.Powered by Capital Market - Live

Jubilant Pharmova announced the resignation of Arvind Chokhany, Chief Financial Officer & Whole Time Director of the Company with effect from 29 July 2025. Powered by Capital Market - Live